Cannabaceae

thcscience_admin
Imlunestrant
Clinical data
Other namesLY3484356
Legal status
Legal status
  • Investigational
Identifiers
  • (5R)-5-[4-[2-[3-(Fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC29H24F4N2O3
Molar mass524.516 g·mol−1
3D model (JSmol)
  • C1C(CN1CCOC2=CC=C(C=C2)[C@@H]3C4=C5C=CC(=CC5=NC=C4C6=C(O3)C=C(C=C6)C(F)(F)F)O)CF
  • InChI=1S/C29H24F4N2O3/c30-13-17-15-35(16-17)9-10-37-21-5-1-18(2-6-21)28-27-23-8-4-20(36)12-25(23)34-14-24(27)22-7-3-19(29(31,32)33)11-26(22)38-28/h1-8,11-12,14,17,28,36H,9-10,13,15-16H2/t28-/m1/s1
  • Key:UVBQMXOKKDCBJN-MUUNZHRXSA-N

Imlunestrant is an experimental selective estrogen receptor degrader developed by Eli Lilly and Company for the treatment of some types of breast cancer.[1][2][3]

References[edit]

  1. ^ Neven, P.; Stahl, N.; Losada, M.J. Vidal; Jimenez, M. Martin; Kaufman, P.A.; Harbeck, N.; Hunt, K.; Carter, S.A.; Bidard, F.C.; Fasching, P.; Aftimos, P.G.; Wheatley, D.; Hamilton, E.P.; Aft, R.; Kulkarni, S.; Ismail-Khan, R.; Karacsonyi, C.; Estrem, S.T.; Ozbek, U.; Ciruelos, E.M. (October 2023). "273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2". Annals of Oncology. 34: S292–S293. doi:10.1016/j.annonc.2023.09.470. S2CID 264385454.
  2. ^ Jhaveri, Komal; O’Shaughnessy, Joyce; Andre, Fabrice; Goetz, Matthew P.; Harbeck, Nadia; Martín, Miguel; Bidard, Francois-Clement; Thomas, Zachary M.; Young, Suzanne; Ismail-Khan, Roohi; Smyth, Lillian M.; Gnant, Michael (1 March 2023). "Abstract OT1-01-02: EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET". Cancer Research. 83 (5_Supplement): OT1–01–02-OT1-01–02. doi:10.1158/1538-7445.SABCS22-OT1-01-02.
  3. ^ Jhaveri, Komal L.; Jeselsohn, Rinath; Lim, Elgene; Hamilton, Erika P.; Yonemori, Kan; Beck, J. Thaddeus; Kaufman, Peter A.; Sammons, Sarah; Bhave, Manali A.; Saura, Cristina; Calvo, Emiliano; Meniawy, Tarek; Larson, Timothy; Ma, Cynthia X.; García-Corbacho, Javier; Cao, Shanshan; Estrem, Shawn T.; Milata, Jennifer L.; Nguyen, Bastien; Beeram, Muralidhar (1 June 2022). "A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER". Journal of Clinical Oncology. 40 (16_suppl): 1021. doi:10.1200/JCO.2022.40.16_suppl.1021. S2CID 249445691.
source: https://en.wikipedia.org/wiki/Imlunestrant

One thought on “Cannabaceae”

  1. Well, that’s interesting to know that Psilotum nudum are known as whisk ferns. Psilotum nudum is the commoner species of the two. While the P. flaccidum is a rare species and is found in the tropical islands. Both the species are usually epiphytic in habit and grow upon tree ferns. These species may also be terrestrial and grow in humus or in the crevices of the rocks.
    View the detailed Guide of Psilotum nudum: Detailed Study Of Psilotum Nudum (Whisk Fern), Classification, Anatomy, Reproduction

Leave a Reply